

HYPOLIP

Atorvastatin Calcium 5/10/20

GENERIC NAME: Atrovastatin

THERAPEUTIC CATEGORY: Antihyperlipidemic

PHARMACOLOGIC CLASS: HMG-CoA Reductase Inhibitor.

COMPOSITION AND PRESENTATION:

Hypolip 5:

Composition:

Film coated tablet Atorvastatin calcium equivalent to 5 mg Atorvastatin

Presentation:

30 tablets X 5 blisters

Hypolip 10:

Composition:

Film coated tablet Atorvastatin calcium equivalent to 10 mg Atorvastatin

Presentation:

30 tablets X 5 blisters

Hypolip 20

Composition:

Film coated tablet Atorvastatin calcium equivalent to 20 mg Atorvastatin

Presentation:

30 tablets X 5 blisters

MECHANISM OF ACTION:

Inhibits the conversion of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase to mevalonic acid by blocking the enzyme HMG- CoA reductase and decrease the concentration of total cholesterol and low density lipoproteins.

INDICATION

- Primary hypercholesterolaemia
- Hyperlipidaemia of diabetes mellitus
- Secondary prophylaxis after MI.

DOSAGE:

Initially 10 mg daily. May be increased upto 80 mg once daily.

PHARMACOKINETIC PROFILE

- Protein Binding: 96 to 98%
- Half-life: 13 to 30 h
- Time to maximum effect: 2 to 3 week.

ADVERSE EFFECT:

- Causes headache, altered liver function test and gastrointestinal effects including nausea, vomiting, diarrhea. Rash and hypersensitivity reaction have been reported rarely.
- Also angioedema, anorexia, neuropathy, impotence, chest pain, hypoglycemia, hyperglycemia reported.

SPECIAL PRECAUTION:

Use with caution in patient with history of liver diseases or who consume excessive amounts of alcohol. liver function tests should be carried out before and within 1-3 months of starting treatment and thereafter at intervals of 6 months for 1 year, unless indicated sooner by sign or symptoms suggestive of hepatotoxicity. Treatment should be discontinued if serum transaminase concentration rises to, and persist at.

CONTRAINDICATION

- Hypersensitivity
- Liver disease
- Trauma
- Surgery

For further information, please contact:

Market Planning Department



Deurali-Janta Pharmaceuticals Pvt. Ltd.

GPO Box 4239, 355 Hattisar Road, Kamalpokhari, Kathmandu, Nepal.

Tel: 4435167/68/69 E-mail: mplanning@deuralijanta.com Website: www.deuralijanta.com

